IP Library › Granted Patent US 12,264,322
Granted Patent B2
US 12,264,322 · App. 17/183,263 · Granted Apr 1, 2025

Minimal volume reprogramming of mononuclear cells

Inventors: Peter Flynn (San Diego, CA); Bahram Valamehr (San Diego, CA)
Assignee: FATE THERAPEUTICS, INC.
C12N15/85A61K35/545A61K2035/124A61K35/51C12N2740/16043C12N2800/108C12N2800/30C12N2840/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,322
App. No.
17/183,263
Granted
Apr 1, 2025
Kind
B2
Abstract

The invention provides compositions and methods for reprogramming minimal volumes of mononuclear cells. In particular aspects, the invention provides methods and compositions for reprogramming minimal volumes of umbilical cord blood obtained from cord blood segments from cryopreserved cord blood segments.

Claims (25)

1. A method for producing induced pluripotent stem cells (iPSC) from an individual segment of an umbilical cord blood unit (UCB) comprising:

providing an individual segment of UCB comprising about 100 to about 1×10 6 of CD34+ mononuclear cells, wherein said CD34+ mononuclear cells comprise CD45+/CD34+/Lineage− cells, and wherein the individual segment of UCB has a minimal volume of less than 500 μL; and

reprogramming the CD34+ mononuclear cells to iPSC using a non-integrating method, wherein the CD34+ mononuclear cells comprise at least one exogenous polypeptide selected from the group consisting of an octamer-binding transcription factor 4 (OCT4) polypeptide, a sex determining region Y box 2 (SOX2) polypeptide and a Simian virus 40 large antigen (SV40LT) polypeptide, wherein reprogrammed iPSC co-express SSEA4 and TRA181 with a reprograming efficiency of at least 5%.

2. The method of claim 1 , wherein the at least one exogenous polypeptide is free of Avian Myelocytomatosis Viral Oncogene Homolog (c-MYC) and Kruppel-like factor 4 (KLF4) polypeptides.

3. The method of claim 1 , wherein the individual segment comprises about 1×10 3 to about 1×10 6 of CD34+ mononuclear cells.

4. The method of claim 1 , wherein the mononuclear cells comprise CD45+/Lineage-progenitor cells with or without being expanded prior to reprogramming.

5. The method of claim 1 , wherein reprogramming further comprises contacting the mononuclear cells with at least one inhibitor selected from the group consisting of: a glycogen synthase kinase 3 (GSK3) inhibitor, a mitogen-activated protein kinase kinase enzyme (MEK) inhibitor, a rho-associated protein kinase (ROCK) inhibitor, and a transforming growth factor β receptor (TGFβR) inhibitor.

6. The method of claim 5 , wherein reprogramming is performed in a culture environment that is (i) free of feeder cells, is (ii) in a defined culture medium or (iii) is both free of feeder cells and is in a defined culture medium.

7. The method of claim 1 , wherein the method further comprises culturing the iPSC after the reprogramming in a further composition comprising a Wnt pathway agonist, a mitogen-activated protein kinase kinase enzyme (MEK) inhibitor, and a rho-associated protein kinase (ROCK) inhibitor, wherein the further composition does not comprise a transforming growth factor β receptor (TGFβR) inhibitor.

8. The method of claim 7 , wherein the culturing is performed in a culture environment selected from the group consisting of a feeder-free environment, a single cell enzymatically disassociated culturing environment, and a defined culture medium environment.

9. The method of claim 7 , wherein the culturing produces ground state iPSCs.

10. The method of claim 1 , wherein the efficiency of the reprogramming is at least 10%.

11. The method of claim 1 , further comprising banking the iPSC produced from the UCB.

12. The method of claim 1 , wherein the iPSCs produced from the UCB are allogeneic to a subject in need of cell therapy and are HLA matched for the subject.

13. The method of claim 1 , wherein the individual segment of UCB is cryopreserved.

14. The method of claim 1 , wherein providing an individual segment of UCB further comprises selecting CD34+ mononuclear cells from the individual segment of UCB.

15. The method of claim 14 , further comprising culturing the selected CD34+ mononuclear cells under conditions suitable to expand the CD34+ mononuclear cells.

16. The method of claim 15 , wherein the culturing is performed under defined culture conditions.

17. The method of claim 14 , wherein selecting is accomplished by Ficoll gradient, fluorescent assisted cell sorting (FACS) or magnetic assisted cell sorting (MACS).

18. The method of claim 14 , wherein the CD34+ mononuclear cells comprise hematopoietic stem or progenitor cells.

19. The method of claim 18 , wherein the hematopoietic stem or progenitor cells are suitable for hematopoietic reconstitution in a subject in need of cell therapy.

20. The method of claim 19 , wherein the hematopoietic stem and progenitor cells are allogeneic to the subject in need of cell therapy and HLA matched to said subject.

21. The method of claim 1 , wherein the individual segment of UCB is cryopreserved, and wherein prior to introducing the at least one exogenous polypeptide to the CD34+ mononuclear cells, the method comprises: selecting CD34+ mononuclear cells from the individual segment of UCB and culturing the CD34+ mononuclear cells under conditions suitable to expand CD34+ mononuclear cells.

22. The method of claim 1 , wherein the volume is between 50 μL and 500 μL.

23. The method of claim 1 , wherein the volume is a volume selected from the group consisting of: less than 400 μL, less than 300 μL, less than 200 μL, less than 100 μL, less than 50 μL, less than 25 μL, and less than 10 μL.

Continuity (4)
Continuation 16007928 · Jun 13, 2018
Division 14731403 · Jun 4, 2015
Provisional Application 62007924 · Jun 4, 2014
Related Publication 20210198687A1 · Jul 1, 2021
References Cited (53)
US 6534476B2 · Miyazono et al. · 2003 [cited by applicant]
US 6692736B2 · Yu et al. · 2004 [cited by applicant]
US 8044201B2 · Xu et al. · 2011 [cited by applicant]
US 8691574B2 · Mack · 2014 [cited by applicant]
US 9624470B2 · Slukvin et al. · 2017 [cited by applicant]
US 11268069B2 · Valamehr · 2022 [cited by examiner]
US 20050119203A1 · Steinbrecher et al. · 2005 [cited by applicant]
US 20090299763A1 · Sakurada · 2009 [cited by applicant]
US 20120135525A1 · Brown et al. · 2012 [cited by applicant]
US 20120252060A1 · Dick et al. · 2012 [cited by applicant]
US 20120315703A1 · Liu · 2012 [cited by examiner]
US 20140294764A1 · Yoon et al. · 2014 [cited by applicant]
US 20200182870A1 · Basso-Ricci et al. · 2020 [cited by applicant]
US 20220228125A1 · Valamehr · 2022 [cited by examiner]
EP 1992360A1 · 2008 [cited by applicant]
WO WO1999001426A1 · 1999 [cited by applicant]
WO WO2002006213A2 · 2002 [cited by applicant]
WO WO2002088346A2 · 2002 [cited by applicant]
WO WO2003077914A1 · 2003 [cited by applicant]
WO WO2005051301A2 · 2005 [cited by applicant]
WO WO2007044084A3 · 2007 [cited by applicant]
WO WO2008006583A1 · 2008 [cited by applicant]
WO WO2008094597A2 · 2008 [cited by applicant]
WO WO2010141801A2 · 2010 [cited by applicant]
Aasen, “Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes,” Nature, (2008); 26(11):1276-1284. [cited by applicant]
Chang et al., “Transforming growth factor-beta signaling in breast cancer,” Front Biosci., (2007); 12:4393-4401. [cited by applicant]
Cui, “Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP”, Oncogene, (2005); 24(24):3864-3874. [cited by applicant]
DaCosta et al., “SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7”, Mol Pharmacol., (2004); 65(3):744-752. [cited by applicant]
De Gouville et al. “Inhibition of ALK5 as a new approach to treat liver fibrotic diseases,” Drug News Perspect., (2006); 19(2):85-90. [cited by applicant]
Donnelly et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” J Gen Virol., (2001); 82(Pt5): 1027-1041. [cited by applicant]
Gafni et al., “Derivation of novel human ground state naive pluripotent stem cells,” Nature, (2013); 504:282-286. [cited by applicant]
Gellibert et al., “Discovery of 4-{4-[3-(pyridin-2-y1)-1 H-pyrazol-4-yl]pyridin-2-y1}-N-(tetrahydro-2H-pyran-4-y1)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I recep… [cited by applicant]
Huang et al., “Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists,” Nucleic Acids Res., (2009); 37(1):1-13. [cited by applicant]
Inman et al., “SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7,” Mol Pharmacol., (2002); 62(1):65-74. [cited by applicant]
Irion et al., “Identification and targeting of the ROSA26 locus in human embryonic stem cells,” Nat Biotechnol., (2007); 25(12): 1477-1482. [cited by applicant]
Jackson et al., “Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond,” RNA, (1995); 1(10):985-1000. [cited by applicant]
Jackson et al., “The novel mechanism of initiation of picornavirus RNA translation,” Trends Biochem Sci., (1990); 15(12):477-483. [cited by applicant]
Kaminska et al., “TGF beta signalling and its role in tumour pathogenesis,” Acta Biochim Pol., (2005); 52(2):329-337. [cited by applicant]
Lee et al., “Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells,” Nat. Biotechnol., (2007); 25:1468-1475. [cited by applicant]
Mian et al., “SF3B1 Mutant Clones From Patients With Refractory Anaemia With Ringed Sideroblasts (RARS) Originate From The Early Haematopoietic Stem Cells and Maintain Their Engraftment Potential,” Blood, (2013); 122(21… [cited by applicant]
Rao et al., “Concise review: cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities,” Stem Cells, (2012); 30:55-60. [cited by applicant]
Rosskopf et al., “Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow),” Vox Sanguinis, (2011); 101:255-275. [cited by applicant]
Ryan et al., “Virus-encoded proteinases of the picornavirus super-group,” J Gen Virol., (1997); 78 (Pt 4):699-723. [cited by applicant]
Shimanuki et al., “Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling,” Oncogene, (2007); 26(23):3311-20. [cited by applicant]
Spellman et al., “Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood,” Cytotherapy, (2011); 13(7):848-855. [cited by applicant]
Suzuki et al., “A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection,… [cited by applicant]
Szymczak et al., “Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector,” Nat Biotechnol., (2004); 22(5):589-594. [cited by applicant]
Tojo et al. “The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta,” Cancer Sci., (2005); 96(11):791-800. [cited by applicant]
Valamehr et al., “A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs,” Sci. Reports, 2:213 (2012). [cited by applicant]
Valamehr et al., “Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells,” Stem Cell Reports, (2014) 2:366-373. [cited by applicant]
Wrzesinski et al., “Transforming growth factor-beta and the immune response: implications for anticancer therapy,” Clin Cancer Res., (2007); 13(18 Pt 1):5262-5270. [cited by applicant]
Yu et al., “Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences,” Science, (2009); 324(5928):797-801. [cited by applicant]
Zhao et al., “Inhibition of transforming growth factor-betal-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA,” Mol Biol Cell., (2006); 17(9):3819-3831. [cited by applicant]